Actively Recruiting
A Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence and Its Clinical Translation Research
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2026-03-03
2000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Breast cancer is a common cancer in women worldwide, with distant metastasis being the main cause of poor outcomes and death. This research aims to develop a precise prediction system using multiple types of data, including digital pathology, immunohistochemistry, proteomics, and gene sequencing, combined with artificial intelligence. The goal is to predict distant and organ-specific metastasis in breast cancer and analyze the underlying mechanisms to support precision medicine. The study observes groups of female breast cancer patients categorized by metastatic risk (high, medium, low), specific organ metastasis sites (bone, lung, liver, brain), and a non-metastatic control group. No interventions or treatments are administered, as this is an observational study focusing on data collection and analysis. The prediction models will be developed and evaluated throughout the study period. Participants will provide clinical data and tissue specimens from primary or metastatic tumor sites stored at the hospital or participating centers. Researchers will track metastasis-free survival from diagnosis until December 30, 2028, and assess the performance of the prediction models at the study's end. The study involves ongoing monitoring of patient data to refine and validate the AI-based prediction system for breast cancer metastasis.
CONDITIONS
Brief Title
Clinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients pathologically diagnosed with breast cancer at the hospital or participating centers between January 1, 2000, and December 30, 2028
- Have developed distant metastasis with biopsy or surgical specimen stored at the hospital and complete clinical information, or have a metastatic site specimen stored at the hospital if the primary tumor specimen is elsewhere
You will not qualify if you...
- Presence of metastatic cancer from another primary cancer
- Incomplete clinical information
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Varies depending on participant data availability
Participants undergo assessments and data collection to evaluate metastatic risk and organ-specific metastasis.
1 to 2 visits depending on data collection needs
Duration - Up to 8 years from diagnosis through December 30, 2028
Participants are monitored for metastasis-free survival and outcomes are recorded up to December 30, 2028.
Periodic visits as per clinical follow-up schedules
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
Research Team
F
Fengbo Huang, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here